Letairis (ambrisentan)
By Business Review Editor
PharmaDeals Review: Vol 2007 Issue 89 (Table of Contents)
Published: 7 Nov-2007
DOI: 10.3833/pdr.v2007i89.259 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Letairis™ (ambrisentan) was recently approved in the US for the treatment of pulmonary arterial hypertension (PAH), a condition in which there is higher than normal blood pressure in the pulmonary artery, which can lead to heart and lung degradation, and eventually, death...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS